Recurrence after Whipple, Folfirinox and Sbrt
Hi all, my mom, 73, had Whipple in Feb 2023. Whipple was successful, totally resected but there WAS lymph node involvement. Did adjuvant Folfirinox for six month and 5 weeks daily radiation, has been on surveillance scans since.
Most recent scan shows two new masses in pancreas. Did a PET, showing moderate metabolic activity. Endoscopy was unable to get at the tumor for biopsy due to reworked anatomy. Ca-19 went from 88 to 150 over a few weeks. So this seems to be recurrence according to oncologist. Getting second opinion from original Whipple surgeon (could it be inflammation, etc). , oncology wants to start new chemo regime soon, Gemcitibine/Amaxabane.
Seems that we have to wait three-four weeks for blood test to see if immunotherapy is an option? Why so long?
Any faster/better options?
I don’t understand rumor tissue testing…would they send the “old” tissue? If they can’t get the new tumor tissue?
Could we get a second Whipple?
Interested in more discussions like this? Go to the Pancreatic Cancer Support Group.
I also wanted to add that the reason I did it was because though the last remaining lesion shrunk from its original size of 1.6 cm to 0.9cm it seemed to stubbornly just stay at that 0.9cm size, so that why I decided to take another approach at it to try and “kill” that area of invasion. Good luck with your plan of action gamaryanne.
Based on my knowledge coming from clinical research and a pancreatic survivor that has listened to case presentations, I recall a scenario where there was increasing CA19-9 but nothing had come up on imaging for quite awhile. Eventually recurrence was found along the surgical bed. I do not recall if imaging was by CT or PET. NanoKnife/IRE was the method of choice. The procedure was done at an NCI Center of Excellence, so a multidisciplinary tumor board evaluated all the particulars of the case in deciding to chose this over SBRT and Proton Therapy. Histotripsy was not available at the time.
NanoKnife was likely decided to be the most appropriate if the area is near critical structures (e.g., bile ducts, major vessels) and surgical resection is not feasible, as it minimizes damage to adjacent critical tissues.
If there is clearly a solid tumor meeting minimum size requirements, Histotripsy is the least invasive method. Recoverynis fast and in blasting a tumor with sound waves, it appears to cause an Abscopal Effect whereby antigens (proteins) on the cell surface have greater exposure to surveillance cells of the immune system. Essentially the tumor is more easily recognizable as “foreign” and antigen-presenting, dendritic, and macrophage cells are activated that can then target any. Circulating tumor cells and micrometastatic sites. Histotripsy is increasing in use but it has unique requirements athwart may complicate its use in those that had prior Whipple surgery. Fibrotic and scar tissues as a result of surgery can interfere with the penetration of sound waves. For this reason, a radiotherapy might be the next more likely treatment procedure.
SBRT is a strong alternative for patients who are not candidates for invasive procedures or when the lesion is amenable to radiation.
Proton Therapy and Histotripsy are less commonly used in this specific scenario. Familiarity is using proton therapy in this situation I am less familiar with. I do know that of the radiotherapy methods, proton beam therapy is the most precise with a pencil point targeting ability, thus reducing collateral Damage to surrounding tissue.
Caution: The radiation approach for me was initially 100% the path I decided on based on readings from this site and outside readings and eventually after consulting with the radiologist that would do the procedure. My medical oncologist just agreed with the path I chose. So this was all based on my logic and my particular situation but obviously concluded with my the radiation oncologist.
Well said stageivsurvivor! Do you agree that proton therapy better for tumors than lesions?
From what I read, Proton therapy is used more commonly on well defined tumors and rarely on lesions.
Sent from Yahoo Mail for iPad